Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.74 |
| ▸ | EYA2 | O00167 | 1/20 | 0.74 |
| ▸ | APP | P05067 | 1/20 | 0.74 |
| ▸ | ACE | P12821 | 1/20 | 0.74 |
| ▸ | BLM | P54132 | 2/20 | 0.70 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.70 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | DRD1 | P21728 | 1/20 | 0.70 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.70 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.70 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.70 |
| ▸ | DRD3 | P35462 | 1/20 | 0.70 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.70 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL114039 | 0.97 | TDP1 (0.75) | TDP1EYA2APPACEBLM | |
| SCHEMBL24896776 | 0.95 | TDP1 (0.70) | TDP1EYA2APPACEBLM | |
| SCHEMBL8700272 | 0.95 | TDP1 (0.70) | TDP1EYA2APPACEBLM | |
| SCHEMBL15026437 | 0.95 | TDP1 (0.70) | TDP1EYA2APPACEBLM | |
| SCHEMBL14392744 | 0.93 | TDP1 (0.64) | TDP1EYA2APPACEBLM | |
| SCHEMBL19700801 | 0.91 | TDP1 (0.61) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL10785292 | 0.89 | TDP1 (0.82) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL7521838 | 0.89 | TDP1 (0.82) | TDP1EYA2APPACEBLM | |
| SCHEMBL11961185 | 0.89 | TDP1 (0.58) | TDP1EYA2APPACEBLM | |
| SCHEMBL19700802 | 0.89 | TDP1 (0.62) | TDP1EYA2APPACEBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117917989-A | Use of a reversible metal electrodeposited electrolyte with pH-adjustable, dynamic glass element with high opacity and excellent rest stability, and electrolyte useful therefor | 代表内华达大学雷诺分校的内华达高等教育系统董事会 | 2024-04-23 | — | — | CN | disclosed |
| EP-4323615-A1 | DYNAMIC GLASS ELEMENT USING REVERSIBLE METAL ELECTRODEPOSITION ELECTROLYTES WITH TUNABLE PH WITH HIGH OPACITY AND EXCELLENT RESTING STABILITY AND ELECTROLYTES USEFUL THEREFORE | Board of Regents of the Nevada System of Higher Education, on Behalf of the University of Nevada, Reno (US) | 2024-02-21 | — | — | EP | disclosed |
| US-20230355815-A1 | ACTIVE DELIVERY OF RADIOTRACERS ACROSS THE BLOOD BRAIN BARRIER | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2023-11-09 | — | — | US | disclosed |
| WO-2022221094-A1 | DYNAMIC GLASS ELEMENT USING REVERSIBLE METAL ELECTRODEPOSITION ELECTROLYTES WITH TUNABLE PH WITH HIGH OPACITY AND EXCELLENT RESTING STABILITY AND ELECTROLYTES USEFUL THEREFORE | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION, ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) | 2022-10-20 | — | — | WO | disclosed |
| US-20170119913-A1 | CONJUGATE COMPRISING A NEUROTENSIN RECEPTOR LIGAND AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2017-05-04 | — | — | US | disclosed |
| US-9480758-B2 | Diagnostic agents selective against metalloproteases | BRACCO IMAGING S.P.A. (IT) | 2016-11-01 | — | — | US | disclosed |
| US-9376373-B2 | Vinyl monomers having chelating functionality | Rohm and Haas Company Dow Global Technologies LLC | 2016-06-28 | — | — | US | disclosed |
| US-9346899-B2 | Polymers having chelating functionality | ROHM AND HAAS COMPANY | 2016-05-24 | — | — | US | disclosed |
| US-20150376116-A1 | VINYL MONOMERS HAVING CHELATING FUNCTIONALITY | ROHM AND HAAS COMPANY | 2015-12-31 | — | — | US | disclosed |
| US-20150299133-A1 | NEUROTENSIN RECEPTOR LIGANDS | 3 B Pharmaceuticals GmbH | 2015-10-22 | — | — | US | disclosed |
| US-20140308304-A1 | LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS, INC. | 2014-10-16 | — | — | US | disclosed |
| US-20140303397-A1 | VINYL MONOMERS HAVING CHELATING FUNCTIONALITY | ROHM AND HAAS COMPANY (US) | 2014-10-09 | — | — | US | disclosed |
| US-20140303337-A1 | POLYMERS HAVING CHELATING FUNCTIONALITY | ROHM AND HAAS COMPANY (US) | 2014-10-09 | — | — | US | disclosed |
| US-20110117015-A1 | Diagnostic Agents Selective Against Metalloproteases | BRACCO IMAGING S.P.A. (IT) | 2011-05-19 | — | — | US | disclosed |
| US-4142061-A | FOR STABILIZING COBALT CABONYL CATALYST | CHEVRON RESEARCH COMPANY (US) | 1979-02-27 | — | — | US | disclosed |
| US-4096191-A | Hydroformylation of olefins using azoxy-dentated ligands | CHEVRON RESEARCH COMPANY (US) | 1978-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110117015-A1 | Diagnostic Agents Selective Against Metalloproteases | MMP3, MMP7, MMP9 | TDP1 2569/4885EYA2 4495/4885APP 902/4885 |
| US-20230355815-A1 | ACTIVE DELIVERY OF RADIOTRACERS ACROSS THE BLOOD BRAIN BARRIER | CD209, ARG1, MYADM | TDP1 258/4885EYA2 4683/4885APP 41/4885 |
| US-20150299133-A1 | NEUROTENSIN RECEPTOR LIGANDS | NTSR1, NTSR2, TACR3 | TDP1 3351/4885EYA2 4730/4885APP 787/4885 |
| US-20150376116-A1 | VINYL MONOMERS HAVING CHELATING FUNCTIONALITY | MVD, MMAB, PAM | TDP1 3855/4885EYA2 4677/4885APP 4350/4885 |
| US-20140308304-A1 | LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | NPC1L1, NPC1, CETP | TDP1 4210/4885EYA2 2252/4885APP 1676/4885 |
| US-20140303397-A1 | VINYL MONOMERS HAVING CHELATING FUNCTIONALITY | MVD, MMAB, PAM | TDP1 3855/4885EYA2 4677/4885APP 4350/4885 |
| US-20170119913-A1 | CONJUGATE COMPRISING A NEUROTENSIN RECEPTOR LIGAND AND USE THEREOF | NTSR1, NTSR2, ADGRF1 | TDP1 2810/4885EYA2 4355/4885APP 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.